MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526664 | Name: PluriSln-1 (NSC 14613)
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PluriSln-1, also known as PluriSln #1 and NSC 14613, is pluripotent cell-specific inhibitor (PluriSIn). PluriSIn #1 induces ER stress, protein synthesis attenuation, and apoptosis in hPSCs. PluriSIn #1 was also cytotoxic to mouse blastocysts, indicating that the dependence on oleate is inherent to the pluripotent state. The use of human pluripotent stem cells (hPSCs) in cell therapy is hindered by the tumorigenic risk from residual undifferentiated cells.

Chemical Structure

PluriSln-1 (NSC 14613)
PluriSln-1 (NSC 14613)
CAS#91396-88-2

Theoretical Analysis

MedKoo Cat#: 526664

Name: PluriSln-1 (NSC 14613)

CAS#: 91396-88-2

Chemical Formula: C12H11N3O

Exact Mass: 213.0902

Molecular Weight: 213.24

Elemental Analysis: C, 67.59; H, 5.20; N, 19.71; O, 7.50

Price and Availability

Size Price Availability Quantity
100mg USD 750.00 2 Weeks
200mg USD 1,050.00 2 Weeks
500mg USD 1,950.00 2 Weeks
1g USD 2,950.00 2 Weeks
2g USD 3,850.00 2 Weeks
5g USD 6,950.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
NSC 14613; NSC-14613; NSC14613; PluriSln-1; PluriSln #1
IUPAC/Chemical Name
N'-phenylisonicotinohydrazide
InChi Key
HUDWXDLBWRHCKO-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H11N3O/c16-12(10-6-8-13-9-7-10)15-14-11-4-2-1-3-5-11/h1-9,14H,(H,15,16)
SMILES Code
O=C(NNC1=CC=CC=C1)C2=CC=NC=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
PluriSIn 1 (NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD), and is a pluripotent cell-specific inhibitor.
In vitro activity:
Cellular and molecular analyses demonstrated that the most selective compound, PluriSIn #1, induces ER stress, protein synthesis attenuation, and apoptosis in hPSCs. Close examination identified this molecule as an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs. PluriSIn #1 was also cytotoxic to mouse blastocysts, indicating that the dependence on oleate is inherent to the pluripotent state. Finally, application of PluriSIn #1 prevented teratoma formation from tumorigenic undifferentiated cells. Reference: Cell Stem Cell. 2013 Feb 7;12(2):167-79. https://pubmed.ncbi.nlm.nih.gov/23318055/
In vivo activity:
To investigate whether PluriSin#1 treatment prevents tumorigenicity of iPSD after cell transplantation, this study intramyocardially injected PluriSin#1- or DMSO-treated iPSD in a mouse model of myocardial infarction (MI). DMSO-treated iPSD readily formed Nanog-expressing tumors 2 weeks after injection, which was prevented by treatment with PluriSin#1. Moreover, treatment with PluriSin#1 did not change the expression of cTnI, α-MHC, or MLC-2v, markers of cardiac differentiation (P>0.05, n = 4). Importantly, pluriSin#1-treated iPS-derived CM exhibited the ability to engraft and survive in the infarcted myocardium. Reference: Cell Cycle. 2014;13(5):762-71. https://pubmed.ncbi.nlm.nih.gov/24394703/
Solvent mg/mL mM comments
Solubility
DMSO 48.6 227.82
DMSO:PBS (pH 7.2) (1:1) 0.5 2.34
Ethanol 20.7 96.89
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 213.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Zhang L, Pan Y, Qin G, Chen L, Chatterjee TK, Weintraub NL, Tang Y. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71. doi: 10.4161/cc.27677. Epub 2014 Jan 6. PMID: 24394703; PMCID: PMC3979912. 2. Ben-David U, Gan QF, Golan-Lev T, Arora P, Yanuka O, Oren YS, Leikin-Frenkel A, Graf M, Garippa R, Boehringer M, Gromo G, Benvenisty N. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013 Feb 7;12(2):167-79. doi: 10.1016/j.stem.2012.11.015. Epub 2013 Jan 11. PMID: 23318055.
In vitro protocol:
1. Zhang L, Pan Y, Qin G, Chen L, Chatterjee TK, Weintraub NL, Tang Y. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71. doi: 10.4161/cc.27677. Epub 2014 Jan 6. PMID: 24394703; PMCID: PMC3979912. 2. Ben-David U, Gan QF, Golan-Lev T, Arora P, Yanuka O, Oren YS, Leikin-Frenkel A, Graf M, Garippa R, Boehringer M, Gromo G, Benvenisty N. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013 Feb 7;12(2):167-79. doi: 10.1016/j.stem.2012.11.015. Epub 2013 Jan 11. PMID: 23318055.
In vivo protocol:
1. Zhang L, Pan Y, Qin G, Chen L, Chatterjee TK, Weintraub NL, Tang Y. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71. doi: 10.4161/cc.27677. Epub 2014 Jan 6. PMID: 24394703; PMCID: PMC3979912.
1: Ben-David U, Gan QF, Golan-Lev T, Arora P, Yanuka O, Oren YS, Leikin-Frenkel A, Graf M, Garippa R, Boehringer M, Gromo G, Benvenisty N. Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell. 2013 Feb 7;12(2):167-79. doi: 10.1016/j.stem.2012.11.015. Epub 2013 Jan 11. PubMed PMID: 23318055. 2: Raja, G. V. (2017). GSK3B regulates epithelial-mesenchymal transition and cancer stem cell properties and is a novel drug target for triple-negative breast cancer.